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Apobec1 complementation factor overexpression
promotes hepatic steatosis, fibrosis,
and hepatocellular cancer
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The RNA-binding protein Apobec1 complementation factor (A1CF) regulates posttranscriptional ApoB mRNA editing, but
the range of RNA targets and the long-term effect of altered A1CF expression on liver function are unknown. Here we studied
hepatocyte-specific A1cf-transgenic (A1cf+/Tg), A1cf+/Tg Apobec1–/–, and A1cf–/– mice fed chow or high-fat/high-fructose diets
using RNA-Seq, RNA CLIP-Seq, and tissue microarrays from human hepatocellular cancer (HCC). A1cf+/Tg mice exhibited
increased hepatic proliferation and steatosis, with increased lipogenic gene expression (Mogat1, Mogat2, Cidea, Cd36)
associated with shifts in polysomal RNA distribution. Aged A1cf+/Tg mice developed spontaneous fibrosis, dysplasia, and HCC,
and this development was accelerated on a high-fat/high-fructose diet and was independent of Apobec1. RNA-Seq revealed
increased expression of mRNAs involved in oxidative stress (Gstm3, Gpx3, Cbr3), inflammatory response (Il19, Cxcl14, Tnfα,
Ly6c), extracellular matrix organization (Mmp2, Col1a1, Col4a1), and proliferation (Kif20a, Mcm2, Mcm4, Mcm6), and a subset
of mRNAs (including Sox4, Sox9, Cdh1) were identified in RNA CLIP-Seq. Increased A1CF expression in human HCC correlated
with advanced fibrosis and with reduced survival in a subset with nonalcoholic fatty liver disease. In conclusion, we show
that hepatic A1CF overexpression selectively alters polysomal distribution and mRNA expression, promoting lipogenic,
proliferative, and inflammatory pathways leading to HCC.

Introduction

The increasing worldwide prevalence of nonalcoholic fatty liver disease (NAFLD) is projected to result in a corresponding
increase in major progressive outcomes, including nonalcoholic steatohepatitis, fibrosis, and hepatocellular cancer (HCC) (1).
These comorbid complications of NAFLD represent a pressing
concern, particularly with the emergence of HCC as an increasingly common worldwide cause of cancer-associated mortality
(2). In addition, because NAFLD progression is associated with
a range of other comorbidities, including cardiovascular disease (the leading cause of death among patients with NAFLD;
ref. 3), there is also an increasing need to understand the role
of both genetic and environmental modifiers in the etiology
and progression of those important comorbidities. Among the
genes identified in NAFLD susceptibility, several have been
implicated in HCC development, including TM6SF2, PNPLA3,
MBOAT7, and APOB, suggesting that alterations in genes that
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regulate critical pathways in hepatic lipid compartmentalization and/or VLDL secretion may play key roles in both NAFLD
development and disease progression (4). In relation to NAFLD
and cardiovascular disease risk, the E167K variant of TM6SF2
(rs 58542929 C/T) is an important modifier of both blood lipid
levels and hepatic steatosis, with the rare T variant conferring
protection against cardiovascular disease because of reduced
hepatic VLDL secretion but with a consequence of increased
steatosis and NAFLD development (5).
The association of cardiovascular disease and NAFLD has
fueled interest in the mechanisms regulating hepatic apolipoprotein B (APOB) and VLDL production in humans, including
the possibility that therapeutic targeting of VLDL secretion
might offer clinical utility as a strategy for lowering plasma lipid levels. While some reports suggest that antisense targeting
of APOB might be feasible without the adverse effects of hepatic steatosis (6), the predominant clinical experience suggests
that reducing lipid levels by inhibiting VLDL secretion also
promotes hepatic steatosis (7, 8), although the long-term consequences are still unknown. Other studies have demonstrated
a role for epigenetic or posttranscriptional gene regulation of
APOB expression, including a role for Apobec1 complementation factor (A1CF), an AU-rich RNA-binding protein, identified in earlier screens for genetic complementation of C-to-U
1
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Figure 1. Young (8- to 14-week-old) A1cf+/Tg mice on chow diet exhibit increased proliferation and hepatic steatosis. (A) Western blot of A1cf transgene
expression in A1cf+/Tg liver using A1CF and FLAG antibodies. (B) Liver/body weight ratio of A1cf+/Tg mice, represented as mean ± SEM, *P < 0.05. Serum
alanine aminotransferase (ALT) and aspartate aminotransferase (AST) in A1cf+/Tg mice (11–13 per genotype). Data are shown as mean ± SEM, **P < 0.01.
Proliferative index expressed as percentage of BrdU-positive hepatocytes (mean ± SEM, n = 6–8), **P < 0.01. (C) H&E- and Oil Red O–stained liver sections
from A1cf+/Tg mice. Scale bars: 50 μm. Hepatic triglyceride (TG) content (mean ± SEM, 7–12 mice), **P < 0.01. (D) Serum TG after 4- or 16-hour fast (n = 11–15
animals per group). Data are mean ± SEM, *P < 0.05. (E) Western blot of serum and hepatic APOB. Polysomal distribution of ApoB RNA upon fractionation
of hepatic cytoplasmic extracts from A1cf+/Tg mice: monosome (fractions 1–6) and polysome (fractions 7–13). Data are representative of 4 separate isolations. Unpaired Student’s t test was used to determine significance between A1cf+/Tg and WT control groups for all experiments.

RNA editing activity of the cytidine deaminase APOBEC1 (9,
10). A1CF is widely expressed in both human and mouse tissues, including at high levels in the liver, where it binds a range
of RNAs, including ApoB and Il6 (11). A1cf-null mice revealed
distinctive alterations in APOBEC1-dependent C-to-U RNA
editing, yet these mice revealed no change in hepatic ApoB
mRNA editing or expression (12, 13). However, neither of those
studies examined the impact of A1cf deletion on the regulation of hepatic lipid metabolism or the longer-range impact for
metabolic liver disease. Earlier studies showed that hepatic
A1CF was upregulated in ob/ob mice and that siRNA knockdown in hepatocytes impaired VLDL secretion (14). These
studies collectively raise the possibility that A1CF might exhibit
both gain- and loss-of-function phenotypes in vivo, consistent
with findings that an A1CF variant allele is a causal gene for regulating serum triglyceride (TG) levels in humans (15).
Here we report studies that address these unanswered questions. We generated liver-specific A1cf-transgenic mice, revealing a phenotype with spontaneous steatosis, fibrosis, and HCC,
none of which were observed in A1cf-null mice. We identified
a range of hepatic A1CF RNA targets and pathways, including
oxidative stress, inflammation, and extracellular matrix organization. Finally, we demonstrate that A1CF was overexpressed
in a subset of patients with HCC. The findings collectively point
2

to a new role for the RNA-binding protein A1CF in liver pathobiology in both mice and humans.

Results

A1cf+/Tg mice exhibit increased hepatocyte proliferation and a subtle
shift in VLDL secretion. We generated two A1cf+/Tg founder lines
(Supplemental Figure 1) with similar expression of the transgene (about 2- to 3-fold above endogenous; Figure 1A), localized predominantly in hepatocyte nuclei (Supplemental Figure
1A). Young (8- to 14-week-old), chow-fed A1cf+/Tg mice revealed
elevated liver/body weight ratios and injury reflected by 2-fold
increased serum alanine aminotransferase (Figure 1B), with no
change in aspartate aminotransferase. We observed increased
BrdU-positive hepatocytes in A1cf+/Tg mice (Figure 1B and
Supplemental Figure 1B) with increased α-fetoprotein (Afp)
mRNA, consistent with increased proliferation (Supplemental
Figure 1B). There were more lipid droplets in A1cf+/Tg mice with
increased hepatic TG content (Figure 1C). Hepatic and serum
total cholesterol and fatty acids (FAs) were unaltered in A1cf+/Tg
mice (Supplemental Figure 1C). Fasting serum TGs were comparable in both genotypes after a 4-hour fast (Figure 1D), but
A1cf+/Tg mice showed no increase following a 16-hour fast compared with controls (Figure 1D and Supplemental Figure 1C),
suggesting subtle impairment of VLDL secretion (16). We also
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Figure 2. Young A1cf+/Tg mice show reduced APOB secretion and smaller VLDL particles. (A) Serum lipoprotein profile (n = 4 per group) following a 4-hour fast
and fractionation by fast protein liquid chromatography. TG and cholesterol levels were biochemically determined. Bottom panel: Electron microscopy of serum
VLDL particles isolated from pooled serum, 4 hours after Pluronic F-127 injection. Scale bars: 500 nm. Unpaired Student’s t test was used to determine significance between groups. Size distribution of VLDL particles is representative of 3 separate evaluations, **P < 0.01. (B) Pulse chase analysis of [35S]-labeled APOB
synthesis and secretion from primary hepatocytes isolated from A1cf+/Tg mice. Autoradiograph is a representative image of 3 independent experiments.

found relatively increased APOB100 in livers of A1cf+/Tg mice,
along with a shift of ApoB mRNA into actively translating polysomal fractions (Figure 1E), further suggesting impaired VLDL
assembly and secretion in these mice. Fractionation of serum
indicated a shift into smaller TG- and cholesterol-containing
VLDL fractions (Figure 2A), with smaller nascent VLDL particles visualized in A1cf+/Tg mice (Figure 2A). In addition, studies
in isolated hepatocytes revealed decreased secretion of APOB
from A1cf+/Tg mice (Figure 2B), even though in vivo VLDL-TG
secretion rates were comparable in both genotypes after either
4- or 16-hour fast (Supplemental Figure 1D). These data collectively suggest that hepatic A1cf overexpression results in
decreased APOB secretion associated with a shift in VLDL
secretion toward smaller particles.
Prompted by findings showing that A1cf deletion in liver-like hepatoma cells decreased APOB secretion (15), we
examined hepatic and serum lipid metabolism in A1cf –/–
mice. However, we found no significant changes in serum or
hepatic TG or cholesterol content and no change in VLDL secretion or in serum or hepatic APOB content or isoform distribution in A1cf –/– mice (Supplemental Figure 2, A–D). We generated
2 independent lines of HepG2 CRISPR-deleted A1CF-null cells
(17), which revealed an approximately 30% decrease in both
APOB synthesis and secretion (Supplemental Figure 2, E and
F). Taken together, these findings suggest that loss of A1CF
slightly decreases APOB production in HepG2 cells but does
not alter APOB expression or VLDL secretion in mouse liver.
A1cf+/Tg mice exhibit altered expression of genes promoting FA
uptake and lipogenesis. We undertook RNA pathway analysis
to understand the changes associated with the spontaneous

hepatic steatosis observed in young A1cf+/Tg mice. Gene ontology revealed enrichment in genes involved in lipid biosynthesis
(Figure 3A), including Cidea, Mogat1, Mogat2, and Cd36 (18–20).
Quantitative PCR (qPCR) revealed a 30-fold increase in Cidea
and Mogat1 mRNAs, a 10-fold increase in Mogat2 mRNA, and
a 2-fold increase in Cd36 mRNA (Figure 3B). We also observed
increased MOGAT1 and MOGAT2 protein abundance in A1cf+/Tg
liver (Figure 3C). Analysis of both Cidea and Cd36 RNAs
revealed a shift into actively translating polysomal fractions
(Figure 4A), associated with approximately 3-fold increased
CD36 and (qualitative) CIDEA protein expression (Figure 4B).
Collectively, these results suggest that hepatic A1CF modulates
genes involved in hepatic lipogenesis and FA utilization as well
as hepatic VLDL assembly and secretion, conceivably by altering polysomal mRNA distribution and translation.
A1cf+/Tg mice develop hepatic fibrosis and spontaneous tumorigenesis, independent of APOBEC1 expression. Aged (~12-monthold) A1cf+/Tg mice exhibited increased fibrosis (Figure 5A) and
fibrogenic mRNA expression, including αSma, Col1a1, and
Col4a1 (Figure 5A), with increased liver/body weight ratio (Supplemental Figure 3A) and increased serum alanine aminotransferase (Supplemental Figure 3A). In addition, there were visible tumors in livers of 12 of 13 aged male A1cf+/Tg mice (Figure
5B) but none in livers of 7 of 7 aged female A1cf+/Tg mice (data
not shown). Because A1CF is a component of the C-to-U RNA
editing machinery and since previous studies have demonstrated that APOBEC1 overexpression promotes promiscuous RNA
editing and tumorigenesis (21, 22), we next asked whether there
was a requirement for APOBEC1 in the tumorigenesis observed
in A1cf+/Tg mice. We generated a compound line of A1cf+/Tg
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Figure 3. Hepatic enrichment in genes
involved in lipid biosynthesis in A1cf+/Tg
mice. Expression profile of liver-enriched
genes in 8- to 14-week-old chow-fed A1cf+/Tg
mice. (A) Enriched KEGG pathways in differentially expressed genes from A1cf+/Tg livers.
Heatmap diagram of the more than 2-fold
differentially expressed genes in A1cf+/Tg mice.
(B) qPCR validation of differentially upregulated genes involved in lipid biosynthesis (n
= 6–7 mice per genotype). Data are mean ±
SEM. Unpaired Student’s t test was used to
determine significance between genotypes,
*P < 0.05, **P < 0.01. (C) Western blot analysis of MOGAT1 and MOGAT2 in livers from
chow-fed A1cf+/Tg mice. Actin was used as
loading control. (n = 4–5 mice per genotype.)

Figure 4. Altered expression of genes promoting fatty acid uptake and lipogenesis in A1cf+/Tg mice. (A) Polysomal distribution of Cd36 and Cidea RNAs from
cytoplasmic extracts from A1cf+/Tg liver. RNA abundance was quantitated by qPCR across monosome (fractions 1–6) and polysome (fractions 7–13). Data are
representative of 3 separate fractionations. (B) Western blot analysis of CD36 in liver of A1cf+/Tg mice using actin as loading control. Data are mean ± SEM. Significance was determined using unpaired Student’s t test, *P < 0.05. Immunohistochemical analysis of CIDEA in liver of A1cf+/Tg mice and littermate controls.
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Figure 5. Hepatic overexpression of A1CF promotes fibrosis and spontaneous tumorigenesis. (A) Representative images of Sirius red–stained A1cf+/Tg and
WT livers. Scale bars: 50 μm. Quantitation of Sirius red–stained area expressed as percentage total area (mean ± SEM). Significance was determined using
unpaired Student’s t test, **P < 0.01 (n = 6). Bottom panel: qPCR evaluation of fibrogenic genes in livers of chow-fed 12-month-old A1cf+/Tg mice. Data are
mean ± SEM (n = 6 per genotype). Unpaired t test was used to determine significance between 12-month-old groups, *P < 0.05. (B) Gross images of liver from
A1cf+/Tg and A1cf+/Tg Apobec1–/– mice at 12 months of age fed a low-fat chow diet. (C) Representative images of H&E-stained liver sections from A1cf+/Tg and
A1cf+/Tg Apobec1–/– mice. The dashed curved lines delineate tumor margin. Scale bars: 100 μm (left) and 50 μm (right). Macroscopic quantitation and size of
nodules showing total number (top) and maximum size (bottom) of tumors.

Apobec1–/– mice, which, at 12 months, exhibited increased liver/body weight ratio (Supplemental Figure 3A) and increased
hepatic TG content, without changes in hepatic cholesterol or
FA content (Supplemental Figure 3B), findings similar to those
in 12-month-old A1cf+/Tg mice. As expected, these A1cf+/Tg Apobec1–/– mice expressed only APOB100 (Supplemental Figure 3A).
These aged, male A1cf+/Tg Apobec1–/– mice also developed similar
numbers of liver nodules when compared with A1cf+/Tg mice (Figure 5C) and again, similarly to A1cf+/Tg mice, exhibited increased
hepatocyte proliferation (Supplemental Figure 3C). Histopathological analysis revealed that 5 of 10 aged A1cf+/Tg Apobec1–/– livers
exhibited dysplastic nodules, with 1 of 5 exhibiting HCC (Table
1), suggesting that A1CF-induced tumorigenesis is likely independent of both APOBEC1 and RNA editing. In addition, because
liver-specific A1cf-knockout mice exhibited aberrant alternative
splicing of ketohexokinase-C RNA (23), a feature associated with
HCC formation (24), we examined 1-year-old male A1cf–/– mice,
but observed no spontaneous tumors (0 of 10 mice; Table 1 and
Supplemental Figure 4A). We observed increased hepatic TG
content in 12-month-old chow-fed A1cf–/– mice, without changes
in cholesterol or FA content, and no change in transaminases but
increased hepatic inflammatory marker mRNA expression for

Ly6c and Ccr2 (Supplemental Figure 4, B and C). We will consider the significance of these findings in a later section, in the
context of high-fat, high-fructose feeding.
Immunohistochemical analysis revealed heat shock protein
70 (HSP70), glypican 3 (GPC3), and p62 staining of tumor cells
in both A1cf+/Tg and A1cf+/Tg Apobec1–/– mice (Figure 6A), with
scattered inflammatory infiltrates and apoptotic and mitotic
figures (Figure 6B). Despite the presence of hepatic steatosis and scattered inflammatory cells, there was no evidence
of increased hepatic inflammation, based on lack of change in
mRNA abundance for inflammation-associated genes in either
genotype at 12 months (Supplemental Figure 5A). We also
observed increased expression of β-catenin (both overall and
nuclear; Figure 6C) as well as its downstream target cyclin D1
in the livers of aged A1cf+/Tg mice (Figure 6C). These findings are
relevant since activation of β-catenin is a key event in HCC (25).
Because of the progressive nature of liver tumorigenesis,
we examined 6-month-old chow-fed male A1cf+/Tg mice, which
revealed small nodules in 4 of 7 mice. These nodules revealed
areas of steatosis, inflammation, hepatocyte ballooning, and
anisonucleosis but were not dysplastic (Supplemental Figure 5B). We also fed groups of male A1cf+/Tg and A1cf –/– mice a
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Table 2. Pathological analysis of livers of 6-month-old A1cf+/Tg
mice fed a trans-fat/fructose diet

Table 1. Pathological analysis of 12-month-old A1cf+/Tg livers
WT

A1cf+/Tg

A1cf+/Tg
Apobec1–/–

WT6NJ

A1cf–/–

No. of animals
No lesion
Nondysplastic lesions
Dysplastic lesions

7
7
0
0

13
1
1
7

10
0
5
4

7
7
0
0

10
10
0
0

HCC

0

4

1

0

0

high-fat, high-fructose diet for 6 months in order to examine
the impact of diet-induced steatosis on hepatic tumorigenesis.
These findings revealed tumors in 9 of 14 A1cf+/Tg mice (Figure
7A and Table 2) and increased STAT3 activation with increased
phospho-STAT3 expression (Figure 7B) along with increased
expression of a known downstream target, Hif1α mRNA (ref. 26
and Figure 7C). We also observed immunohistochemical staining for GPC3 and HSP70 (Figure 7D) and increased expression
of β-catenin (Figure 7E) in tumor nodules from A1cf+/Tg mice. By
contrast and consistent with our observations in aged chow-fed
mice, no tumors were observed in high fat–, high fructose–fed
A1cf –/– mice (Figure 7A), and there was no change in hepatic
expression of β-catenin in these mice (Figure 7F). A1cf –/– mice
exhibited fibrotic injury comparable to that seen in WT6NJ
controls, with increased hepatic mRNA expression of Col4a1
and Spp1, along with increased mRNA expression of several
inflammatory genes (Supplemental Figure 6, A and B), a pattern similar to that described above in 12-month-old chow-fed
A1cf –/– mice (Supplemental Figure 4C). These findings together imply that the hepatic steatosis and inflammatory signaling
observed in both chow- and high fat–, high fructose–fed A1cf –/–
mice are insufficient to drive tumor initiation.
Transcriptome-wide analysis of A1cf+/Tg liver and isolated hepatocytes. The findings to this point demonstrate that
A1cf+/Tg mice exhibit alterations in mRNAs involved in hepatic
lipogenic and VLDL assembly pathways, but raise questions
regarding the mechanisms associated with the fibrogenic and
tumorigenic phenotypes observed. As an approach to identify
those pathways, we undertook RNA-Seq and STRING analysis (27) (https://string-db.org/) to examine functional enrichment and protein-protein interaction networks from whole
liver transcriptomes in young (12-week-old) mice (Figure 8A).
Those analyses revealed changes in several functional categories, including cell cycle, extracellular matrix organization, TG metabolism, and lipid particle organization as well
as oxidative stress (Figure 8A). qPCR validated upregulation
of several target mRNAs involved in these pathways (Figure
8B). The mRNA changes in regard to cell cycle and extracellular matrix organization extend findings illustrated above showing increased proliferation and fibrogenesis in A1cf+/Tg mice.
We pursued the findings implicating altered oxidative stress in
A1cf+/Tg mice and found that total glutathione levels were significantly elevated in A1cf+/Tg liver (Supplemental Figure 7A), with
no change in reduced or oxidized glutathione and no change in
mRNAs involved in glutathione synthesis (Supplemental Figure
6

Animals
No lesion
Nondysplastic lesions
Dysplastic lesions

WT

A1cf+/Tg

WT6NJ

A1cf–/–

8
8
0
0

14
5
2
7

9
9
0
0

12
12
0
0

7A). We also found no evidence for increased endoplasmic reticulum stress as evidenced by mRNA abundance of Chop, Ire1a,
Xbp1, Grp78, and Atf4 (Supplemental Figure 7B).
To further examine the range of potential A1CF mRNA targets, we undertook sequencing of RNA isolated by crosslinking
immunoprecipitation (RNA CLIP-seq) of RBP-RNA complexes
(28) on isolated hepatocytes from A1cf+/Tg mice (Supplemental
Figure 7C) and identified 245 RNAs that copurified with FLAGtagged A1CF (here designated direct A1CF targets). Overlapping
these direct A1CF RNA targets with mRNAs that were significantly differentially expressed in our RNA-Seq studies, we identified
4 A1CF RNA targets (Sox4, Sparcl1, Smad9, and Dlgap1) (Figure
9). qPCR revealed 1.5-fold and 2-fold upregulation of Sox4 and
Sparcl1 mRNAs, respectively, with 2-fold and 10-fold downregulation of Smad9 and Dlgap1 mRNAs, respectively (Figure 9).
These mRNAs revealed a trend toward the inverse patterns in
A1cf –/– liver (Supplemental Figure 7D). SOX4 overexpression in
liver was shown to stabilize β-catenin and increase cell proliferation, promoting steatosis and HCC progression (29–32), while
SPARCL1 overexpression was correlated with tumor angiogenesis in HCC (33, 34). Since SMAD9 inhibits bone morphogenetic
protein (BMP) signaling (34), we asked whether the decreased
expression of Smad9 in A1cf+/Tg liver was accompanied by changes in Bmp7 mRNA. qPCR revealed a 2-fold increase in A1cf+/Tg liver (Supplemental Figure 7E), findings consistent with the fibrogenic phenotype observed in A1cf+/Tg mice. These findings, taken
together, support the notion that mRNAs identified through
RNA CLIP are likely direct A1CF targets with a plausible role in
the phenotypes observed. Among the differentially expressed
RNAs, we also observed increased abundance of several organogenic mRNAs (Sox9, Gpc1, Tmprss4) in A1cf+/Tg mice (Supplemental Figure 7F). Among the features of interest in these mRNAs,
the presence of an AU-rich 3′-UTR in Sox9 mRNA led us to ask
whether Sox9 mRNA could represent a target for A1CF, since
earlier work showed that A1CF is an AU-rich RNA-binding protein (11). Here we show that Sox9 RNA was immunoprecipitable
from liver extracts and demonstrated a shift into actively translating polysomal RNA fractions (Supplemental Figure 7F).
We also undertook transcriptome profiling in isolated
hepatocytes, revealing 391 upregulated and 574 downregulated RNAs (Figure 10A). Cd36 mRNA was approximately 4-fold
upregulated (compare Figure 10A with Figure 3B for whole
liver), again supporting the conclusion that hepatocyte Cd36
expression is regulated in response to A1CF overexpression.
We aligned A1CF RNA targets identified by RNA CLIP with
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Figure 6. Increased expression of HCC markers in 12-month-old A1cf+/Tg mice. (A) Representative images of HSP70 and p62 expression in HCC from
12-month-old A1cf+/Tg mice. Representative images of hepatic GPC3 in 12-month-old A1cf+/Tg and A1cf+/Tg Apobec1–/– mice. Arrowheads indicate clusters
of GPC3-positive cells. (B) Representative H&E images of pathological features identified in 12-month-old A1cf+/Tg liver. Left panel: Arrow indicates focal
inflammation. Arrowheads indicate apoptotic cells. Right panel: Arrowhead indicates mitotic body. (C) Immunohistochemical staining of 12-month-old
A1cf+/Tg livers with β-catenin antibody. Expression of β-catenin in liver tissue from A1cf+/Tg and littermate controls evaluated by Western blot and compared
with actin. Representative images of cyclin D1 in liver from 12-month-old A1cf+/Tg mice. All panels, scale bars: 50 μm.

differentially expressed RNAs in A1cf+/Tg hepatocytes and validated differential expression of 2 mRNAs, Dram1 and Phlda2,
which showed 2- to 2.5-fold higher levels in A1cf+/Tg hepatocytes
(Figure 10B). Gene Ontology analysis revealed enrichment of
pathways related to inflammatory response, supporting the
phenotype observed in A1cf+/Tg liver (Figure 11A) and consistent with a predicted increase in production of proinflammatory cytokines and chemokines (35), including IL19, Cxcl14, and
TNFα mRNAs, which were 5- to 12-fold upregulated in A1cf+/Tg
hepatocytes (Figure 11A). We also analyzed markers of inflammation in whole liver from A1cf+/Tg mice and observed a significant increase in mRNAs encoding proinflammatory chemokines
including CCR2 and CXCL14 that likely contribute to inflammation, as shown by elevated expression of Ly6c and Tnfα mRNAs
(Figure 11A). In addition, we examined expression of mRNAs
encoding tumor suppressor genes (TSGs) and oncogenes (Figure
11B), revealing 49 TSG mRNAs and 2 oncogene mRNAs among
the differentially expressed genes from the RNA-Seq analysis. Of
the 49 TSG mRNAs, 26 clustered in functional categories including transcriptional regulation, cell cycle, and protein phosphorylation, supporting the phenotype observed in A1cf+/Tg. Among the
26 TSG mRNAs, 7 showed more than 3-fold alteration by RNASeq, of which 4 TSG mRNAs (Pbrm1, Rb1, Sall2, and Cdh24), validated by qPCR, were significantly downregulated (Figure 11B),

while 2 oncogenes (Jak3, Klf4) exhibited increased mRNA abundance in A1cf+/Tg liver (Figure 11B).
Whole liver transcriptome analysis in aged A1cf+/Tg liver. The
data presented above suggest that A1CF overexpression promotes steatosis and hepatocyte proliferation as well as activating inflammatory and fibrogenic pathways in both whole liver
and isolated hepatocytes from young mice. In order to understand the tumorigenic pathways in older mice, we next profiled
mRNAs in aged (12-month-old) A1cf+/Tg liver, which revealed
1505 differentially expressed RNAs (Figure 12A). Gene Ontology and Kyoto Encyclopedia of Genes and Genomes (KEGG)
analysis revealed enrichment in genes related to extracellular
matrix organization (Figure 12B). We aligned differentially
expressed RNAs with RNA CLIP A1CF targets and identified 6
A1CF RNA targets: 4 with increased abundance (Spag5, Phlda2,
Abcc12, and Cdh1) and 2 with decreased abundance (Dmrta1 and
Irx1) in A1cf+/Tg livers (Figure 12C and Figure 13). We attempted
to assign a definitive role for A1CF in the regulation of these
RNAs by examining hepatic mRNA expression in aged A1cf –/–
mice, reasoning that mRNAs that were increased in A1cf+/Tg
livers would be correspondingly reduced in the livers of A1cf –/–
mice. Of the 6 RNAs identified above, only E-cadherin 1 (Cdh1)
met the criteria for a gain-of-function/loss-of-function effect
(i.e., upregulated in A1cf+/Tg and downregulated in age-matched
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Figure 7. Accelerated hepatic tumorigenesis in A1cf+/Tg mice fed a trans-fat/fructose diet. (A) Top: Gross images of liver from A1cf+/Tg and A1cf–/– mice fed
a trans-fat/fructose diet for 6 months. Bottom: H&E staining revealing fat accumulation in all genotypes but dysplastic nodules (dashed area) only in
A1cf+/Tg liver. Scale bars: 100 μm. (B) Western blot analysis of STAT3 activation/phosphorylation at Tyr 705. p-STAT3 was normalized to total STAT3 (n = 7
A1cf+/Tg and 4 WT). Unpaired Student’s t test was used to determine significance between groups, *P < 0.05. (C) Expression of STAT3 downstream target,
Hif1α RNA, by qPCR. Data are mean ± SEM (n = 7 A1cf+/Tg and 4 WT), **P < 0.01 determined by unpaired Student’s t test. (D) Representative images of
GPC3- and HSP70-stained sections from A1cf+/Tg mice. Distinct nodules are delineated by dashed curved lines. GPC3 staining shows rare cells staining with
cytoplasmic positivity within the nodule (arrowheads). Positive HSP70 staining in liver nodule, supporting neoplastic progression. Scale bars: 50 μm. (E
and F) Expression of β-catenin in liver from 7 A1cf+/Tg and 4 WT mice (E) and 5 A1cf–/– mice and 5 aged-matched WT6NJ mice (F). Expression of β-catenin
normalized to actin is shown as β-catenin/actin ratio. Significance was determined using unpaired Student’s t test, *P < 0.05.

A1cf –/– liver) (Figure 13). Abcc12 mRNA was 5-fold upregulated in A1cf+/Tg liver, recapitulating findings showing increased
expression in breast cancer (36), and loss of A1CF attenuated
this increase in mRNA expression (Figure 13). The remaining
4 RNAs (Spag5, Phlda2, Dmrta1, Irx1) were unchanged in WT
and A1cf –/– liver (Figure 13 and Supplemental Figure 8). We
examined features of the 12 mRNAs identified through RNA
CLIP-Seq as possible A1CF targets, focusing on the 3′-UTR
(Supplemental Table 1). The majority of these mRNAs (11 of 12)
were enriched in AU sequences, containing at least 1 AUUUA
motif or stretches (5 or 6 repeats) of poly(U) elements (Supplemental Table 1). These sequence and context preferences are
consistent with findings from earlier studies (37). Only 1 mRNA
(Abcc12) contained none of these features and contained less
than 50% AU content (Supplemental Table 1).
A role for A1CF in human HCC. Genome-wide association studies implicate A1CF in regulating hepatic lipid metabolism and plasma TG levels (15). Because genetic pathways in
hepatic lipid metabolism modulate HCC risk in patients with
NAFLD (38), we took advantage of The Cancer Genome Atlas
(TCGA) and observed that 6 A1CF RNA targets (Spag5, Abcc12,
Phlda2, Cdh1, Dmrta1, and Irx1; Supplemental Figure 9A) that
8

were differentially expressed in 12-month-old A1cf+/Tg mouse
liver were also associated with aberrant expression of A1CF in
human HCC. Of the 6 RNAs, Spag5 and Cdh1 mRNAs showed
a significant positive co-occurrence with A1CF (Supplemental
Figure 9A). Alterations in A1CF were observed in 9% of 360
patients with HCC, including increased gene copy number
and increased mRNA expression in a subset as well as reduced
A1CF expression in another subset, the latter reflecting either
decreased mRNA or mutational alteration (Supplemental Figure
9A). These findings hint at the possibility that A1CF expression
might be altered in patients with HCC.
To resolve that possibility, we examined immunohistochemical expression of A1CF in normal control subjects, cirrhotic
patients, and patients with HCC. We observed homogeneous
nuclear A1CF staining in control subjects (Figure 14A, top), with
heterogeneous staining in cirrhotic nodules as well as in HCC
with increased nuclear expression at the edge of the invasive
front of the tumor (Figure 14A, bottom, arrowheads). We also
performed immunohistochemical analysis of A1CF expression in a tissue microarray of human HCC samples generated
at Mayo Clinic, Rochester, Minnesota (clinical data included
in Supplemental Table 2). We categorized A1CF staining into 4
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Figure 8. Differentially expressed genes in livers from young
A1cf+/Tg mice. (A) Heatmap of the 556 differentially expressed
genes. STRING analysis of the differentially expressed genes
showing enriched pathways. (B) qPCR validation of gene
clusters involved in extracellular matrix organization (red),
cell cycle (blue), and oxidative stress (green). Data are mean ±
SEM (n = 6–8), *P < 0.05, **P < 0.01 (unpaired t test).

groups based on average sample pixel intensity per high-power
field, in both tumor and uninvolved tissue (Figure 14B and Table
3). A high level of A1CF staining correlated with advanced (F3/4)
fibrosis in both uninvolved and tumor tissue from the entire
cohort (Figure 14C) and was also correlated with higher levels
of α-fetoprotein levels (Figure 14D). We used multivariable Cox
proportional hazard modeling to show that A1CF staining intensity in the uninvolved tissue was predictive of overall survival,
with worst survival associated with highest levels of A1CF
expression. This implied prognostic role of increased A1CF
staining intensity was independent of TNM stage, tumor number, and other putative prognostic factors included in the final
model (Supplemental Table 3). Among a subgroup of 19 HCC
patients in whom NAFLD was a potential underlying etiology
(Methods and Supplemental Table 4), the adverse prognostic
role of increased A1CF staining intensity was further substantiated with a progressive decrease in overall survival apparent
in patients with increasing levels of A1CF expression (Figure
14E). Furthermore, using proportional hazard modeling, we
found that A1CF expression remained predictive of survival

after adjustment for recurrence and time to first recurrence in
the subgroup with NAFLD (Supplemental Table 5). We also confirmed a significant, independent association of mRNA expression of A1CF with SPAG5 and with CDH1 in a second cohort of
patient samples (Supplemental Table 6) of normal and cirrhotic
liver (Supplemental Figure 9B), suggesting that the associations
demonstrated in mice overexpressing A1cf may also be relevant
to conditions (e.g., cirrhosis) that predispose to HCC in humans.

Discussion

Here we show that transgenic overexpression of the RNA-binding protein A1CF in mouse liver produces a gain-of-function
phenotype that includes steatosis, increased proliferation,
inflammation, fibrosis, and spontaneous tumorigenesis. As an
overarching model (Figure 15), we show that A1CF overexpression alters hepatic APOB secretion and shifts VLDL production
into smaller particles, which, along with upregulation of mRNAs
including lipogenic genes and Cd36, promotes the development of hepatic steatosis. In addition, upregulation of mRNAs
involved in oxidative stress, inflammation, and extracellular

J Clin Invest. 2021;131(1):e138699 https://doi.org/10.1172/JCI138699

9

RESEARCH ARTICLE

The Journal of Clinical Investigation  

Figure 9. Schematic representation of differentially expressed genes in young A1cf+/Tg mice in relation to A1CF RNA CLIP targets. Two A1CF RNA targets
(Sox4 and Sparcl1) are upregulated (red) and 2 (Smad9 and Dlgap1) are downregulated (blue) in A1cf+/Tg liver. Expression of these 4 targets was validated by
qPCR (n = 7–8) and is shown as mean ± SEM, *P < 0.05, **P < 0.01 (unpaired t test).

matrix organization in A1cf+/Tg mice promotes the development
of hepatic fibrosis. The convergence of these steatotic and fibrogenic pathways, together with upregulation of proliferative
and organogenic mRNAs and decreased expression of tumor
suppressor mRNAs, promotes spontaneous tumorigenesis and
HCC (Figure 15). Several elements of our findings and this proposed model merit further discussion.
A1CF is a widely expressed RNA-binding protein identified in connection with ApoB RNA binding and assembly of a
functional C-to-U RNA editing complex with APOBEC1 (9, 10).
However, A1cf deletion produced no effect on ApoB RNA editing
(12) and variably impacted C-to-U RNA editing of other mRNAs
(13). More recently, genome-wide association studies implicated variants in A1CF with specific metabolic traits, including regulation of plasma TG levels (15, 39). Accordingly, among the primary objectives of this study was to examine the impact of gain
and loss of function of A1CF alleles on hepatic RNAs and in particular the impact on VLDL assembly and secretion. Findings
demonstrating that CRISPR-mediated A1CF deletion in human
hepatoma cells greatly decreased APOB secretion (15) led us
to predict that VLDL production and fasting plasma TG levels
would be correspondingly reduced in A1cf+/Tg mice and elevated
in A1cf –/– mice. However, these predictions were only partially
confirmed. We found a modest decrease in APOB secretion and
a shift to smaller VLDL particles in A1cf+/Tg mice. However, there
were no alterations in hepatic TG or VLDL secretion or in APOB
production in A1cf –/– mice and only a subtle (~30%) decrease in
APOB secretion from 2 independent A1CF-null HepG2 cells.
Our transcriptomic surveys further revealed a panel of hepatic mRNAs whose expression was upregulated in A1cf+/Tg mice,
including Cidea, Mogat1, Mogat2, and Cd36, via mechanisms
that include shifts into actively translating polysome fractions
and increased protein expression. A function for A1CF in transporting mRNAs toward actively translating polysomes is consistent with its known nuclear/cytoplasmic shuttling activity in cell
culture models (14, 40) and with its dynamic pattern of altered
distribution under metabolic stress (23).
We further observed that aged A1cf+/Tg mice developed
advanced fibrosis and that male mice developed spontaneous
liver tumors at high penetrance, even while consuming a chow
diet. The tumorigenic phenotype was accelerated when male
10

mice were fed a high-fat, high-fructose diet, and these mice
exhibited hepatic STAT3 activation along with downstream
effects including upregulation of Hif1α mRNA, consistent with
prior studies linking experimental obesity-associated nonalcoholic steatohepatitis to advanced features including development of HCC (41). These tumors exhibited features associated with human HCC, including immunohistochemical
staining for GPC3 and HSP70, enhanced β-catenin expression,
and increased expression of cyclin D1. Certain features of the
temporal progression from steatosis to fibrosis raise the question of whether the development of HCC in A1cf+/Tg mice occurs
as a consequence of — or independently from — fibrogenic and
inflammatory signaling. The demonstration that A1cf+/Tg mice
fed high-fat, high-fructose diets exhibit enhanced steatosis and
inflammatory signaling (augmented STAT3 activation; Figure
7, A and B) along with dysplastic nodules suggests that the progressive development of HCC is likely driven by steatotic injury
and fibrogenic signaling. On the other hand, our findings that
WT and A1cf –/– mice also develop steatosis, fibrosis, and inflammation when fed high-fat, high-fructose diets, yet mice of neither genotype develop tumors at 6 months (in contrast to A1cf+/Tg
mice), suggest that the presence of steatosis and fibrosis alone is
insufficient to promote HCC.
As a step toward identifying relevant signaling pathways,
we undertook RNA-Seq from livers of A1cf+/Tg mice at various
ages and aligned some of the differentially expressed mRNAs
with RNA CLIP-Seq from isolated hepatocytes. We identified
12 mRNAs through RNA CLIP-Seq and discovered several
shared sequence motifs within the 3′-UTR of these mRNAs,
including the overall AU content, the presence and multiplicity
of AUUUA motifs, and the presence and multiplicity of poly(U)
stretches. The preferences for AU and poly(U) motifs are consistent with recent work (37), and these preferences are shared
by other RNA-binding proteins, including RBM47 and members of the hnRNP family (hnRNPH1/2), both of which have
been shown to interact with A1CF in posttranscriptional regulation (13, 23). Among the RNA CLIP targets, Cdh1 and Spag5
both have plausible roles in the pathogenesis of HCC. Germline or somatic (loss-of-function) mutations in CDH1 are well
recognized in a range of cancers, including HCC (42, 43), but
CDH1 mRNA has also been shown to be upregulated in 40% of
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Figure 10. Differentially expressed genes in primary hepatocytes from
young A1cf+/Tg mice in relation to A1CF RNA CLIP targets. (A) Heatmap of
966 differentially altered genes in primary hepatocytes from A1cf+/Tg mice.
Upregulation of Cd36 RNA in A1cf+/Tg hepatocytes represented as mean ±
SEM (n = 6), **P < 0.01 (unpaired t test). (B) Venn diagram showing two
A1CF RNA CLIP targets (Dram1 and Phlda2) upregulated in A1cf+/Tg hepatocytes with mRNA expression, validated by qPCR, shown as mean ± SEM
(n = 6), *P < 0.05 (unpaired t test).

patients with HCC (44), with findings demonstrating selective
nuclear retention of CDH1 mRNA in some patients (45). These
latter findings raise the question of whether nucleocytoplasmic
shuttling activity of A1CF (40) plays a role in compartmentalizing specific cargo RNAs in tumorigenesis. Another A1CF target,
SPAG5, was upregulated (mRNA and protein) in HCC and associated with poor survival (46). Furthermore, expression of both
CDH1 and SPAG5 RNA was highly correlated with A1CF RNA in
patients with cirrhosis (Supplemental Figure 9B). Yet another
A1CF target, Sox9 mRNA, which was immunoprecipitated from
hepatocytes from A1cf+/Tg mice, was identified as a hepatic stem
cell marker in HCC with SOX9 overexpression in patients correlating with reduced overall survival (47).
As for other RNA targets, A1CF likely interacts with RBM47
in the context of C-to-U RNA editing of ApoB mRNA and modifies editing activity of the RNA deaminase APOBEC1 on a
variety of substrates in mouse liver and intestine (13). A1CF competes with hnRNPH1/2 by binding at the 5′ splice site of exon

3C in ketohexokinase mRNA and regulates alternative splicing
(23). However, we failed to observe spontaneous liver tumors in
aged, male A1cf –/– mice, in which this alternative splicing event
would be predicted to increase expression of ketohexokinase
mRNA with the A isoform, a shift in isoform distribution that
was shown in other work to promote growth of hepatoma cells
in nude mice (24). An additional caveat is warranted in the
interpretation of the temporal shifts in hepatic mRNA expression noted in A1cf+/Tg mice since those changes likely reflect both
altered cellular expression and cellular composition. Resolution
of these possibilities will require study of the cellular composition and transcriptomic profiles at critical developmental stages.
While we confirmed the same pattern of nuclear A1CF
staining in human hepatocytes and mouse liver (48), we also
observed heterogeneity in A1CF expression in cirrhosis and
HCC with variability in regenerating nodules and tumors. We
found that increased levels of staining were associated with
more advanced stages of fibrosis as well as other parameters
of advanced liver disease (Child-Pugh score and MELD score)
(Supplemental Table 2). In HCC patients in whom NAFLD was
an underlying etiology, high levels of A1CF staining were predictive of reduced overall survival. These observations must
be interpreted with caution, however. First, this cohort of
HCC contained only 19 subjects (14%) with NAFLD, and our
study was not powered to draw conclusions regarding specific HCC etiology. However, the overall prevalence of NAFLD
underlying HCC is very similar to that in previous retrospective cohorts reported from the Mayo Clinic (49). Second, while
fibrosis stage is an important predictor of all-cause mortality in
NAFLD patients (50), it is unclear whether A1CF expression is
associated with compensated cirrhosis and/or bridging fibrosis.
This reservation is relevant also to our observations that A1CF
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Figure 11. A1cf+/Tg primary hepatocytes show enrichment in inflammatory response pathways. (A) Gene Ontology analysis showing functional pathways overrepresented (red) and underrepresented (blue) in A1cf+/Tg hepatocytes. Relative expression of genes involved in inflammatory response examined by qPCR, in both
isolated hepatocytes and whole liver (5–8 per genotype). Data are mean ± SEM, *P < 0.05, **P < 0.01 (unpaired t test). (B) Venn diagram representing comparative
analysis between genes with differentially altered expression in A1cf+/Tg hepatocytes and Tumor Suppressor Gene (TSG) and Oncogene databases. qPCR validation
of a subset of TSG and Oncogene RNAs from 4–5 independent hepatocyte isolations per genotype. Data are mean ± SEM, *P < 0.05, **P < 0.01 (unpaired t test).

staining is within hepatocytes, suggesting the possibility that
steatotic hepatocytes release factors that promote fibrogenic and/or inflammatory signaling (51). Third, our conclusions
regarding A1CF expression in those samples reflect immunohistochemical staining intensity, which is at best semiquantitative. Future studies will be required to obtain a more granular
understanding of A1CF protein distribution and expression in
relation to the candidate mRNAs implicated and to examine the
role of RNA trafficking, polysome distribution, and translation
of those candidate target genes.

Methods

Animals. A1cf–/– and Apobec1–/– mice were on a background of
C57BL/6NJ or C57BL/6J, respectively (13, 52). For high-fat diet studies, mice were fed a high–trans-fat, high-fructose diet (TD.06303,
Envigo) for 6 months. Unless noted otherwise, mice were fasted for 4
hours and injected with 100 mg/kg of BrdU (Sigma-Aldrich) 2 hours
before study. Littermate controls were used in all experiments.
Generation of A1cf-transgenic mice. The FLAG-A1cf transgene
was generated by amplification of A1CF from human cDNA using a
5′ primer containing FLAG sequence and a KpnI site and a 3′ primer
containing an XhoI site and cloned into the pLiv7 vector (53). Of 5
founders, 2 were selected with comparable levels (about 2- to 3-fold)
of transgene expression for the baseline characterization and original
description of spontaneous tumorigenesis.
Liver and serum biochemical assessments. Serum levels of alanine
aminotransferase and aspartate aminotransferase were measured with
kits (ALT [SGPT], A526-120, and AST [SGOT], A559-150, respectively,
12

Teco Diagnostics). Serum and hepatic triglycerides (TGs), cholesterol,
and nonesterified fatty acid levels were measured using kits (L-Type
Triglyceride M, 998-02891/998-02892; Cholesterol E, 996-02611;
and HR Series NEFA-HR(2) 991-34793/999-35193, respectively, all
from FUJIFILM Wako Diagnostics). Serum was fractionated on tandem Superose 6 columns (Pharmacia FPLC). Liver glutathione was
evaluated following manufacturer’s protocol (Cayman Chemical).
VLDL secretion. Following a 4- or 16-hour fast, mice were weighed
and injected with Pluronic F-127 (1 mg/g; Invitrogen) and serum TG
determined from blood collected 1, 2, and 4 hours after injection.
Electron microscopy. Pooled serum from 2–4 mice was collected
after Pluronic F-127 injection and VLDL particles separated by ultracentrifugation for negative staining electron microscopy.
Histology and immunohistochemistry. For mouse studies, BrdU-positive hepatocytes were quantitated in each section. Eight to ten fields
per section, each section containing 4–6 pieces of liver from multiple
lobes, were analyzed. Fibrosis was assessed by Sirius red staining.
Using Nuance multispectral imaging software, a spectral library was
created to analyze a complete experimental group. Liver sections (4
μm) were stained with anti-A1CF, anti-FLAG, anti-CIDEA, anti–β-catenin, anti-HSP70, anti-GPC3, anti-p62, and anti–cyclin D1. Dilutions
and origins of each antibody are given in Supplemental Table 7. Histological survey was performed by a pathologist blinded to the experimental groups. Liver nodules were counted and classified into dysplastic nodules and HCC. The background liver was evaluated for the
presence of steatosis, inflammation, ballooning, and anisonucleosis.
For human samples, tissue microarray slides were scanned using a
Nuance FX multispectral imaging system (CRi, Cambridge Research
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Figure 12. Summary of differentially expressed genes in liver of 12-month-old chow-fed A1cf+/Tg mice. (A) Heatmap showing expression of 1505 differentially expressed genes in A1cf+/Tg liver. (B) Gene Ontology analysis depicting functional categories overrepresented (red) and underrepresented (blue) in
A1cf+/Tg livers. (C) Venn diagram summarizing comparative analysis between 1505 differentially altered genes in A1cf+/Tg liver and A1CF RNA targets identified by RNA CLIP. Six A1CF RNA targets showed altered expression, with 4 (Spag5, Abcc12, Phlda2, and Cdh1) upregulated (red) and 2 (Dmrta1 and Irx1)
downregulated (blue). Expression was confirmed by qPCR (6–8 animals per genotype). Data indicate mean ± SEM, *P < 0.01, **P < 0.05 (unpaired t test).

& Instrumentation) and Nuance 2.10 software. Images were acquired
at 20 nm wavelength intervals and combined into 1 image. A spectral
library was created and served as reference with individual fluorescent signals corresponding to total A1CF, nuclear A1CF, counterstain
(hematoxylin), and autofluorescence. Autofluorescence was subtracted from the spectral reference. Two ×20 magnification fields per sample were randomly analyzed. The emission spectra for total and nuclear
A1CF were acquired and saved as an image cube that contained both
individual signal components, which were then unmixed and analyzed
separately. The intensity of staining was defined by pixels evaluated in
the analyzed area, including the entire field for total A1CF staining and
all nuclei for nuclear staining. Total pixel values for total and nuclear
A1CF represent the mean of 2 measurements per sample. Stained area
was expressed as a percentage of total area. Unstained samples were
evaluated using the same parameters used to create the spectral reference (fluorescent signals for both total and nuclear A1CF, counterstain,
and autofluorescence). These samples showed only counterstaining
background. Samples were considered positively stained when the
total pixel value was above counterstain background.
Studies in primary hepatocytes. Livers were perfused and digested
with 0.05% collagenase (Type IV, C5138, Sigma-Aldrich), and hepatocytes were plated on collagen-coated dishes overnight. APOB synthesis
and secretion were studied as previously described (54), with 35S-methionine pulsed for 30 minutes and chased for 0, 2, and 4 hours. Aliquots
of cell lysate and medium were immunoprecipitated with APOB IgG and
separated by 4%–15% gradient SDS-PAGE. The data were normalized to
total TCA-precipitable radioactivity. CRISPR-targeted HepG2 cells were
generated as previously described (17).
RNA extraction and RNA-Seq. For each genotype and condition,
3 pools were prepared, each containing RNAs from 3–4 separate
mice, for a total of 10 mg RNA per final pool. Pools were subjected to

oligo-dT selection, cDNA library preparation, and whole transcriptome sequencing by Illumina HiSeq2000 as previously described (55).
Gene expression analysis by qPCR. Total RNA was treated with
DNase and subjected to cDNA synthesis using a High Capacity
cDNA Reverse Transcription kit (Applied Biosystems). qPCR was
performed in triplicate. RNA levels were expressed as fold changes
after normalization to Gapdh RNA. Sequences of primers used for
qPCR are listed in Supplemental Table 8.
Polysome isolation. Livers were washed in ice-cold PBS supplemented with 0.1 mg/mL cycloheximide (Sigma-Aldrich) and minced
in lysis buffer (25 mM Tris-HCl [pH 7.5], 250 mM NaCl, 5 mM MgCl2,
0.5 mM PMSF, 0.2 mg/mL heparin [Sigma-Aldrich], 5 mM DTT, 20 U/
mL RNasin [Promega], 0.1 mg/mL cycloheximide, 1% Triton X-100,
1× protease inhibitor). Homogenized minced livers were resolved
through a 10%–50% sucrose gradient at 200,000g for 2.5 hours at
4°C using a SWT41i rotor (Beckman Brea). Fractions (0.9 mL) were
collected and 260 nm absorbance monitored by spectrophotometry.
RNA from each fraction was used for qPCR.
Protein extraction and Western blot analysis. Fifty micrograms
protein was resolved by SDS-PAGE and transferred to PVDF membrane. In all analyses, equal loading was verified using anti-actin or
anti-GAPDH antibody. Antibodies and conditions used for Western
blot are listed in Supplemental Table 7.
A1CF-RNA coimmunoprecipitation. A1CF-RNA coimmunoprecipitation was performed as previously described (11). Freshly harvested, minced livers were exposed to 300 mJ/cm2 UV irradiation in a
Stratalinker 1800 (Stratagene), collected in 1× PBS, and resuspended
into PLB buffer (10 mM HEPES [pH 8], 100 mM KCl, 5 mM MgCl2,
10 mM ribonucleoside vanadyl complexes [Sigma-Aldrich], 0.5%
Nonidet P-40, 1 mM DTT, 0.2 mM PMSF, and protease inhibitors).
Cleared lysates were incubated with 0.1 mL of pre-swollen magnetic
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Figure 13. Expression profile of
differentially expressed A1CF RNA
CLIP targets in 12-month-old A1cf–/–
mice. Heatmap representation of 298
genes with altered expression in liver
of 12-month-old chow-fed A1cf–/– mice.
Expression of A1CF RNA targets,
differentially expressed in 12-monthold A1cf+/Tg, in liver of 12-month-old
A1cf–/– mice. Genes upregulated in aged
A1cf+/Tg mice are indicated in red; genes
downregulated are indicated in blue.
RNA-Seq analysis showed that of the
6 genes identified from RNA-Seq and
RNA CLIP in A1cf+/Tg mice, only Cdh1
was both upregulated in A1cf+/Tg mice
and downregulated in A1cf–/– mice. Cdh1
RNA expression in A1cf+/Tg and A1cf–/–
liver was confirmed by qPCR (n = 6–7
per genotype). Data represent mean ±
SEM, *P < 0.05 (unpaired t test).

Table 3. Distribution of patients by A1CF expression category in
uninvolved and tumor tissue
A1CF expression
Category
1
2
3
4
Total

Number of patients
Uninvolved
39
45
23
20

Tumor
36
36
30
35

127

137

Dynabeads protein A beads (Invitrogen). Aliquots were extracted
with TRIzol as input RNA. The remainder was incubated overnight,
with either protein A coupled to anti-A1CF (25 μg), or rabbit IgG in
NT2 buffer (50 mM Tris [pH 7.4], 150 mM NaCl, 1 mM MgCl2, 0.05%
Nonidet P-40) supplemented with 200 U of RNase inhibitor (Invitrogen), 2% ribonucleoside vanadyl complexes, 1 mM DTT, and 150 mM
EDTA. The beads were washed twice in buffer A (1× PBS [no Mg2+, no
Ca2+], 0.1% SDS, 0.5% deoxycholate, 0.5% Nonidet P-40), twice in
buffer B (5× PBS [no Mg2+, no Ca2+], 0.1% SDS, 0.5% deoxycholate,
0.5% Nonidet P-40), and twice in buffer C (50 mM Tris [pH 7.4],10
mM MgCl2, 0.5% Nonidet P-40). Beads were incubated 30 minutes
at 55°C with 30 μg of proteinase K (Sigma-Aldrich) and 0.1% SDS in
1× NT2 buffer supplemented with 80 U of RNase OUT (Promega).
The phenol/chloroform-extracted RNA was used for cDNA synthesis followed by PCR using Sox9-specific primers: Fwd825 5′-GAAGAGACCCTTCGTGGAGGAGGCGG-3′; Rev1040 5′-TGCACCTCACTCATGCCGGAGGAGG-3′. PCR products from A1CF-specific
immunoprecipitation were gel-purified and sequenced.
RNA CLIP-Seq was performed as previously described (28).
Primary hepatocytes (108) from 12-week-old A1cf+/Tg mice seeded
on 10 mm collagen-coated plates were exposed to 400 mJ/cm2 of
254 nm UV light in a Stratalinker 2400 (Stratagene). Hepatocytes
were scraped in 1 mL lysis buffer containing 50 mM HEPES (pH
7.5), 150 mM KCl, 2 mM EDTA, 1 mM NaF, 0.5% (vol/vol) NP40, 1
14

mM DTT, 1× protease inhibitors, 2 mM Na3VO4, 5 mM sodium pyrophosphate, and RNasin (Promega), incubated on ice, and frozen at
–80°C. Cells were homogenized, and cleared lysates were treated
with RQ1 DNase (Promega) for 5 minutes at 37°C followed by 15
minutes of incubation at room temperature with RNase T1 (Fermentas). A1CF-RNA complexes were immunoprecipitated and
treated on-beads with RNase T1, ligated with RNA adapters (RL5aTYE705 and RL3-biotin), resolved on SDS-PAGE, and transferred
to nitrocellulose. The RNP complexes were excised and treated
with Proteinase K (Thermo Scientific). Phenol/chloroform-purified RNA was subjected to cDNA synthesis using DP3 primer, followed by PCR using DP5a and DP3 primers. PCR conditions were
as follows: 94°C for 2 minutes; 40 cycles at 94°C for 30 seconds,
58°C for 30 seconds, 68°C for 30 seconds; 68°C for 10 minutes.
PCR products were gel-purified and subjected to a second round of
amplification using DSFP5a and indexed DSFP3 primer (RPIX-D3)
(1 per template) with the following conditions: 94°C for 2 minutes;
35 cycles at 94°C for 30 seconds, 62°C for 45 seconds, 68°C for
45 seconds; and 68°C for 10 minutes. Final PCR products were
gel-purified and submitted for high-throughput sequencing using
primer SSP1. Primer sequences were as follows: RL5a-TYE705:
5′-AGGGAGGACGAUGCGG-3′; RL3-biotin: 5′-GGCGACCUUCACUGACUGUG-3′; DP5a: 5′-AGGGAGGACGATGCGG-3′; DP3:
5′-CCGCTGGAAGTGACTGACAC-3′; DSFP5a: 5′-AATGATACGGCGACCACCGACTATGGATACTTAGTCAGGGAGGACGATGCGG-3′; RPIX1-DP3: 5′-CAAGCAGAAGACGGCATACGAGATCGTGATGTGACTGGAGTTCCTTGGCACCCGAGAATTCCACCGCTGGAAGTGACTGACAC-3′. The underlined 6-nucleotide
sequence represents the index. Each index is as follows: RPIX2DP3: ACATCG; RPIX3-DP3: GCCTAA; RPIX4-DP3: TGGTCA; RPIX5-DP3: CACTGT; RPIX6-DP3: ATTGGC; RPIX7-DP3:
GATCTG; RPIX8-DP3: TCAAGT; RPIX9-DP3: CTGATC; SSP1:
5′-CTATGGATACTTAGTCAGGGAGGACGATGCGG-3′.
Bioinformatics analysis. Microarray data was processed using the
R/Bioconductor package limma (51). Background correction was performed using the normexp + offset method (56). The loess and scale
methods (57) were used for normalization within and between arrays,
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Figure 14. A1CF expression inferred from immunohistochemical staining in human HCC tissue microarray. (A) Top: A1CF staining of normal human liver
showing homogeneous strong nuclear expression. Scale bars: 50 μm. Bottom: A1CF in cirrhotic and HCC tissue. Staining shows a gradient of expression
with strong nuclear A1CF staining at the edge of cirrhotic nodules and tumor (arrowheads). Scale bars: 50 μm (first 3 panels) and 20 μm (last panel). (B)
A1CF expression in 137 human samples from a tissue microarray. Samples were categorized according to A1CF staining evaluated by quantitation of pixels (see Methods). A representative image of each category is shown. Scale bars: 50 μm. (C) A1CF expression and comparison among fibrosis categories
in uninvolved and tumor tissues from all patients. Data represent mean ± SEM (unpaired t test). (D) A1CF expression in uninvolved tissue and comparison among patients with low and high levels of AFP, represented as mean ± SEM (unpaired t test). (E) Kaplan-Meier plots of the overall survival rates
in HCC subjects with underlying NAFLD, stratified by A1CF staining intensity. Patients were divided into 4 quartiles based on A1CF total expression in
uninvolved tissue. Patients with highest A1CF staining (quartile 4) show significantly reduced survival compared with patients with lower A1CF staining
intensity (quartiles 1–3). Inset shows Cox proportional hazard values.

respectively. RNA-Seq reads were aligned to the Ensembl release 76
primary assembly with STAR version 2.5.1a (58). Unsupervised hierarchical clustering of samples was performed with Cluster3 (59), and
heatmaps were generated with Java TreeView (60). Gene counts were
derived from the number of uniquely aligned unambiguous reads by
Subread:featureCount version 1.4.6-p5 (61). Isoform expression of
known Ensembl transcripts was estimated with Salmon version 0.8.2
(62). All gene counts were imported into the R/Bioconductor package
edgeR (63), and TMM normalization size factors were calculated to
adjust for differences in library size. The TMM size factors and the
matrix of counts were imported into the R/Bioconductor package
limma (64). Weighted likelihoods based on the observed mean-variance relationship of every gene and sample were calculated for all
samples with voomWithQualityWeights (65). Differential expression
analysis was performed to analyze for differences between conditions, and the results were filtered only for the genes with Benjamini-Hochberg false discovery rate adjusted P values less than or equal
to 0.05. The Database for Annotation, Visualization and Integrated
Discovery (DAVID) tool (66, 67) was used to identify enrichment for
functional pathways within differentially expressed gene sets.
Data availability. The RNA-Seq and RNA CLIP data discussed
in this publication were deposited in the NCBI’s Gene Expression Omnibus and are accessible through GEO Series accession
number GSE157233 (https://www.ncbi.nlm.nih.gov/geo/query/acc.
cgi?acc=GSE157233). The RNA array data are accessible through

GEO Series accession number GSE157516 (https://www.ncbi.nlm.
nih.gov/geo/query/acc.cgi?acc=GSE157516).
Studies with human subjects. Deidentified human liver tissue
blocks were obtained from the Department of Pathology at Washington University School of Medicine. For the evaluation of HCC
samples, a total of 137 patients were analyzed from a patient cohort
at Mayo Clinic, Rochester, Minnesota. A tissue microarray was
constructed using 2 uninvolved and 2 tumor tissue samples per
patient, which were analyzed for A1CF expression by immunohistochemistry. Available clinical and laboratory data are presented in
Supplemental Table 2. Patients were followed for an average of 3.7
years after diagnosis. Patients were classified as having NAFLD as
an underlying component of HCC (a) if confirmed by history and
pathological examination or (b) if they had a BMI greater than 30
(>25 for Asians) and there was no other identified etiology (viral hepatitis, alcohol, etc.). A1CF expression was defined as total pixels per
high-power field and categorized as follows: category 1 (less than 12 ×
104 pixels), category 2 (12 × 104 to 23 × 104 pixels), category 3 (23 × 104
to 32 × 104 pixels), category 4 (greater than 32 × 104 pixels). A second
set of patient samples was obtained from cirrhotic and normal liver
tissue in a cohort of patients undergoing surgical resection at Queen
Mary Hospital, Hong Kong. Demographic data for these subjects are
shown in Supplemental Table 6.
Statistics. Data are mean ± SEM for the indicated sample number. Statistical significance was set at a P value less than 0.05. Data
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Figure 15. Schematic summary of findings with an integrated mechanism for A1CF-induced hepatic carcinogenesis. Hepatic overexpression of A1CF
induces steatosis via pathways including increased expression of lipogenic genes, increased fatty acid/lipid uptake (Cidea, Mogat1, Mogat2, Cd36), and
reduced VLDL APOB secretion. Increased A1CF expression is also associated with increased oxidative stress (Gstm3, Gpx3, Cbr3), augmented inflammatory response (Il19, Cxcl14, Tnfα, Ccr2, Ly6c), and exaggerated extracellular matrix organization (Mmp2, Col1a1, Col4a1, Sparcl1), which together promote
accumulation of collagen and fibrosis. In parallel, hepatic overexpression of A1CF increases expression of proliferative genes (Mcm2, Mcm4, Mcm6,
Kif20a), organogenic genes (Bmp7, Sox4, Sox9, Tmprss4), and oncogenic genes (Jak3, Klf4, Tmprss4) and decreases expression of tumor suppressor
genes (Pbrm1, Rb1, Sall2, Cdh24). These adaptive responses, including steatosis, fibrosis, and augmented proliferation, combine to promote spontaneous hepatic carcinogenesis in A1cf+/Tg mice.

were analyzed using GraphPad Prism 7.02 (GraphPad Software Inc.)
by unpaired t test or Mann-Whitney U test. For multigroup comparisons, statistical differences were performed by 1-way ANOVA and
Tukey’s multiple-comparison post hoc test.
Statistical analyses on the clinical samples were performed
using the average A1CF expression of paired samples (pixel count
per high-power field) per tissue type. Unpaired t test or 1-way ANOVA was used to compare A1CF expression of tumor or uninvolved
tissue across subgroups of HCC patients categorized based on different clinical and paraclinical parameters. For survival analysis, we
used Kaplan-Meier curves to estimate overall survival patterns in
patients with different levels of A1CF expression. We also used Cox
proportional hazard modeling to adjust the prognostic role of A1CF
expression in HCC patients for other putative prognostic factors.
First, simple Cox models were used to identify factors associated
with overall survival of patients. Next, we fit the preliminary multivariable model based on A1CF and other candidate factors identified from the previous step and used backward elimination method to reach the final multivariable Cox proportional hazard model.
Prognostic factors with significant hazard ratios or major contribution to fitness of the model were retained in the final Cox model. We
16

also investigated the prognostic role of tissue A1CF expression in a
subset of HCC patients with NAFLD (n = 17/19; Supplemental Table
4). The association between A1CF expression and overall survival
was also adjusted for recurrence and time to the first recurrence
in this subgroup. Statistical analysis of clinical data was conducted
using Stata statistical software version SE 11.2 (StataCorp LP).
Study approval. All animal experiments were conducted in accordance with the guidelines of the Institutional Animal Care and Use
Committee of Washington University School of Medicine (IACUC
20180266, 20190028). Collection of samples from the Mayo Clinic
patient cohort was approved by the Mayo Clinic Institutional Review
Board (IRB 16-003945). Collection of samples from the Hong Kong
patient cohort was approved by the Institutional Review Board of the
University of Hong Kong/Hospital Authority Hong Kong West Cluster.
For the TMAs, not all the patients provided written informed consent.
Both patients who provided written informed consent and deceased
patients who did not opt out of research, as required by Minnesota
law, have previously been approved by the Mayo Clinic Institutional
Review Board for inclusion in our Hepatobiliary Neoplasia Biorepository (IRB 707-03). TMAs were assembled from paraffin blocks from
these patients stored in the Mayo Pathology Tissue Archives.
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